Live Breaking News & Updates on Expanded indication

Stay informed with the latest breaking news from Expanded indication on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Expanded indication and stay connected to the pulse of your community

Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results

Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines

Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022; Excluding...

Argentina , China , Japan , Australia , Canada , United-states , Argentine , Adempas-verquvo , Patritumab-deruxtecan , Gardasil , Robertm-davis , Daiichi-sankyo-biologics

U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...

Brazil , Australia , Japan , Andrew-villani , Traci-mccarty , Biomarin-rareconnections , Hank-fuchs , William-wilcox , Committee-for-medicinal-products-human-use , Biomarin-pharmaceutical-inc , European-commission , Emory-university

NeuroStar Achieves Milestone Regulatory Clearance in South Korea

First International Approval for Expanded Indication and Certification for MT Cap and D-Tect™ TechnologiesMALVERN, Pa., July 17, 2023 -- Neuronetics, Inc. , a medical technology company focused...

South-korea , United-states , Korea , South-korean , Keithj-sullivan , Neurostar-advanced-therapy-for-mental-health , Neuronetics-inc , Public-health , Ministry-of-food , Nasdaq , First-international-approval-for-expanded-indication

Spark Aligners Does It Again With Market Leading Innovation And New FDA Approval To Give Doctors Greater Control And Flexibility – Africa News Wire

Spark Aligners Does It Again With Market Leading Innovation And New FDA Approval To Give Doctors Greater Control And Flexibility – Africa News Wire
za.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from za.com Daily Mail and Mail on Sunday newspapers.

Trevor-nichols , Sharon-scott , Nicole-scheffler , Eric-conley , Ormco-corporation , Spark-approver-software-enhancements , New-features , Expanded-indication , Mixed-dentition , Treat-kids , Home-run , Clear-aligner-system

KemPharm Scores FDA Nod For ADHD Drug, MNOV Quits COVID-19 Vaccine Race, UTHR Gives Up On Trevyent

(2)
NEW YORK CITY (dpa-AFX) - Today's Daily Dose brings you news about KemPharm scoring regulatory nod for its ADHD drug, expanded FDA approval for Pfizer's Lorbrena, United Therapeutics scrapping the development of Trevyent, Vir Biotechnology closing the enrollment in VIR-7831 arm of ACTIV-3 trial, and Takeda securing global rights to Ovid's investigational medicine Soticlestat.
Read on.
1.KemPharm Scores FDA Nod For ADHD Drug
KemPharm Inc. (KMPH) soared more than 42% on Wednesday, following FDA approval of AZSTARYS (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older.

India , Japan , Bharat , Takeda-shonan , Johnson-concerta , Ovid-soticlestat , Vir-biotechnology-inc , Glaxosmithkline , Magenta-therapeutics-inc , Corium-inc , Ocugen-inc , Pfizer

Worldwide IV and Oral Iron Drugs Industry to 2026 - Increasing Availability of Branded Iron Therapeutics and Expanded Indication Approvals Presents Opportunities

Share this article
Share this article
ResearchAndMarkets.com's offering.
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report
The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021-2026.
The global IV and oral iron drugs market is expected to grow due to the prevalence of iron deficiency (ID). This deficiency is a highly widespread nutritional disorder, affecting around one-fourth of the global population, especially women and children. It is one of the predominant causes of anemia. Anemia accounts for around 9% of the total global disease burden. Several chronic diseases are frequently associated with iron deficiency anemia (IDA) such as chronic kidney disease (CKD), chronic heart failure, cancer, and inflammatory bowel diseases. As anemia is associated with chronic fatigue, diminished well-being, and impaired cognitive function, the treatment with oral and IV iron drugs reduces the need for blood transfusion in patients. Further, the WHO rates ID as the most common and widespread nutritional disorder globally, and its prevalence is expected to grow with the aging population and the incidence of various chronic disorders.

Australia , Japan , United-states , United-kingdom , Argentina , Brazil , China , South-africa , Canada , Dublin , Ireland , Germany

IV and Oral Iron Drugs Market Size to Reach Revenues of around USD 10 Billion by 2026

IV and Oral Iron Drugs Market Size to Reach Revenues of around USD 10 Billion by 2026
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

United-states , Canada , America , Ferinject-injectafer , Vifor-pharma , Daiichi-sankyo , Pfizer , Daiichi-sankyo-company , Vifor-pharma-group , Ciron-drugs-pharmaceuticals , Allergan , Route-of-administration